Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.50USD
8 Dec 2017
Change (% chg)

$-0.03 (-5.66%)
Prev Close
$0.53
Open
$0.62
Day's High
$0.63
Day's Low
$0.49
Volume
302,559
Avg. Vol
96,681
52-wk High
$2.80
52-wk Low
$0.49

Chart for

About

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more... (more)

Overall

Beta: 0.40
Market Cap(Mil.): $19.05
Shares Outstanding(Mil.): 38.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 57.47 15.67
EPS (TTM): -- -- --
ROI: -- 13.36 34.62
ROE: -- 20.03 16.00

BRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium

* TROVAGENE PRESENTS DATA SHOWING SENSITIVITY OF TRIPLE NEGATIVE BREAST CANCER (TNBC) CELL LINES TO PCM-075 AND SYNERGY WITH ZYTIGA® AT SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) Source text for Eikon: Further company coverage:

Dec 07 2017

BRIEF-Trovagene Inc updates on clinical trial for PCM-075

* Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075

Nov 13 2017

BRIEF-TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12

* ‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​ Source text: (http://bit.ly/2hgteK4) Further company coverage:

Nov 09 2017

BRIEF-Trovagene files for offering of up to $17.5 mln- SEC filing

* Trovagene Inc files for offering of up to $17.5 million - SEC filing Source text: (http://bit.ly/2zOQs1P) Further company coverage:

Oct 25 2017

BRIEF-Trovagene's PCM-075 demonstrates Synergy with Zytiga

* Trovagene Inc - ‍announced positive data from preclinical research demonstrating synergy of PCM-075 in combination with abiraterone (Zytiga)​

Oct 18 2017

BRIEF-Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075

* Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML)

Oct 09 2017

BRIEF-Trovagene files for offering of upto sale 4.64 mln shares of common stock by the selling stockholders‍​

* Trovagene Inc files for offering of up to sale 4.64 million shares of common stock by the selling stockholders‍​ - SEC Filing Source text: (http://bit.ly/2fELxf1) Further company coverage:

Sep 29 2017

BRIEF-Trovagene appoints Athena Countouriotis to its board of directors

* Trovagene strengthens board of directors with appointment of oncology development veteran Dr. Athena Countouriotis Source text for Eikon: Further company coverage:

Sep 20 2017

BRIEF-Trovagene reports positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor with investigational flt3 inhibitor

* Trovagene's plk1 inhibitor pcm-075, in preclinical aml data, significantly enhances the efficacy of a flt3 inhibitor in combination therapy

Aug 16 2017

BRIEF-Trovagene Q2 loss per share $0.26

* Trovagene announces second quarter 2017 company highlights and financial results

Aug 09 2017

Earnings vs. Estimates